An examination of payer coverage for multiple sclerosis drugs shows variation in how these drugs are covered and in the evidence that payers review to make these decisions.
Jordan E. Anderson, BA
Advertisement
Articles by Jordan E. Anderson, BA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
How the Chai Discovery–Eli Lilly Collaboration Could Advance the Future of AI-Driven Biologics Development
2
Apixaban vs Rivaroxaban: A Clearer Choice for VTE?
3
First-Ever Guideline on Cardio-Kidney-Metabolic Syndrome Calls for Earlier Screening, Coordinated Care
4
Peptide Therapy for Weight Loss: Separating Clinical Promise From Social Media Hype
5